Seeking to disrupt the NGS market, Oxford Nanopore is rolling in cash. Before we heard the news, we sat down with CEO Gordon Sanghera to talk about the company’s success.
December has been a stellar month for Oxford Nanopore. Just over a week ago, Oxford Nanopore’s MinION device was used to sequence the whole genome of a number of human samples for the first time. Just now, the company announced that it has closed a whopping €120M round of fundraising, the largest in Europe this year, to expand its commercial activities and push its technology into the Asian market.
With its portable NGS technology, Oxford Nanopore is challenging big-name competitors like Illumina and Thermo Fisher. While these competitors are building machines for specialized life science labs, this company is democratizing genome sequencing to make it available to nonspecialized users. As Sanghera remarked, “We think long and hard about ubiquitous DNA sequencing and design the technology so that anybody can do it.”
To realize its disruptive approach,